Santaris-chairman: Major loan to ensure survival
In order to make ends meet and ensure security, Santaris Pharma will assume a loan from its investors. There is some uncertainty concerning milestone payments and the loan will help the Danish biotech company to take the coming crucial steps.
af LEONORA BECK
Santaris Pharma is struggling to bring the company’s great medicine hope Miravirsen for hepatitis C through clinical development phases. The company has no real income from products or licenses, and it is still waiting for milestone payments – payments that may never come.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Cash-strapped Santaris soldiers on
For abonnenter
.jpg&w=384&q=75)
